Tirzepatide vs Semaglutide: Mechanism, Dosing, and Evidence

By DoseGauge Editorial · Updated 2026-06-12 · 5 min read

The core difference is the receptor target. Tirzepatide (sold as Mounjaro and Zepbound) is a dual agonist that activates both the GIP and GLP-1 receptors. Semaglutide (sold as Ozempic and Wegovy) is a single GLP-1 receptor agonist. Both are once-weekly subcutaneous injections. In the SURPASS-2 head to head trial, tirzepatide produced larger reductions in HbA1c and body weight than semaglutide 1 mg over 40 weeks. None of that is a recommendation. A clinician matches a drug and dose to a person.

Mechanism

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics the GLP-1 incretin hormone, which increases glucose-dependent insulin secretion, slows gastric emptying, and reduces appetite.

Tirzepatide adds a second target. It activates the glucose-dependent insulinotropic polypeptide (GIP) receptor as well as the GLP-1 receptor, which is why its labels describe it as a dual GIP and GLP-1 receptor agonist. The clinical relevance of adding GIP activity is an active research area, but the receptor pharmacology is the clean, factual line between the two drugs.

The brands map to indications rather than to chemistry. Tirzepatide is sold as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management and, more recently, moderate to severe obstructive sleep apnea in adults with obesity. Semaglutide is sold as Ozempic for type 2 diabetes and as Wegovy for weight management and cardiovascular risk reduction in specific populations. Same molecule, different brand and approved use, in each case. That is why a question about a brand is really a question about an indication and a dose range, not about a different drug.

Dosing and administration

Both drugs are once-weekly subcutaneous injections that start low and titrate up to limit gastrointestinal effects. The schedules differ.

If you reconstitute either compound from a lyophilized vial, the dose-to-units conversion is the same arithmetic for both. The milligrams differ by an order of magnitude, so do not reuse one drug's unit count for the other. Run each one through its own calculator.

What the head-to-head evidence shows

SURPASS-2 is the direct comparison. It randomized adults with type 2 diabetes to tirzepatide 5, 10, or 15 mg or to semaglutide 1 mg, all once weekly for 40 weeks. The mean HbA1c reductions were 2.01, 2.24, and 2.30 percentage points for tirzepatide 5, 10, and 15 mg, versus 1.86 percentage points for semaglutide 1 mg. For body weight, tirzepatide produced greater reductions, with estimated treatment differences versus semaglutide of 1.9 kg, 3.6 kg, and 5.5 kg at the 5, 10, and 15 mg doses.

Two caveats keep this honest. The trial compared specific doses, and semaglutide is approved up to 2 mg weekly for diabetes and higher for the Wegovy weight-management indication, so SURPASS-2 is not a comparison at every dose. And a single trial in one population does not settle which drug is right for any individual.

It also helps to read the HbA1c numbers in context. All four arms produced large reductions from baseline, and the gap between the best tirzepatide arm and semaglutide 1 mg was about 0.44 percentage points of HbA1c. The body-weight gap was larger in relative terms. Both findings are averages across a trial population. An average difference does not predict what any single person will experience, and it does not account for tolerability, cost, access, or the other factors a prescriber weighs.

Side effects at a glance

Both drugs are gastrointestinal-predominant. In SURPASS-2 the most common adverse events were gastrointestinal and mostly mild to moderate, including nausea, diarrhea, and vomiting at broadly similar rates across the tirzepatide and semaglutide arms. Both labels also carry the same boxed warning about thyroid C-cell tumors seen in rodents and the same contraindication in people with a personal or family history of medullary thyroid carcinoma or MEN 2. For the tirzepatide detail, see tirzepatide side effects.

FAQ

Is tirzepatide stronger than semaglutide?

In SURPASS-2, tirzepatide produced larger average reductions in HbA1c and body weight than semaglutide 1 mg over 40 weeks. That is a dose-specific trial result, not a universal ranking, and it does not account for the higher semaglutide doses approved since.

Can you switch between them?

Switching between GLP-1 based drugs is a clinical decision involving dose conversion and re-titration. The labels do not provide a simple swap, and the milligram scales are not interchangeable. That is a conversation for your prescriber.

Do they use the same injection schedule?

Both are once weekly. The starting doses and step sizes are different, so the schedules are not interchangeable even though the cadence matches.

Are the milligram doses comparable between the two drugs?

No, and treating them as comparable is a common mistake. Tirzepatide is dosed up to 15 mg weekly while semaglutide injection is dosed in the single-milligram range. The numbers sit on different scales, so a milligram of one is not equivalent to a milligram of the other. If you reconstitute either from a vial, run that drug's own milligram dose through its own calculator and never reuse a unit count across the two.

Why do both carry the same thyroid warning?

Both are incretin-based drugs, and in rodent studies each was associated with thyroid C-cell tumors. The FDA labels for both therefore carry a boxed warning about that rodent finding and contraindicate use in people with a personal or family history of medullary thyroid carcinoma or MEN 2. The human relevance of the rodent finding is described in the labels as not determined.

Informational and educational only. Not medical advice. DoseGauge computes from the values you enter and does not recommend a dose. Talk to a licensed clinician before using any peptide or GLP-1 medication.